<DOC>
	<DOCNO>NCT02092532</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy intravitreal aflibercept injection ( IAI ) patient neovascular polypoidal choroidal vasculopathy .</brief_summary>
	<brief_title>Intravitreal Aflibercept Neovascular Polypoidal Choroidal Vasculopathy ( RIVAL Trial )</brief_title>
	<detailed_description>This open-label , non-randomized , unmasked , study IAI patient choroidal neovascularization secondary polypoidal choroidal vasculopathy ( PCV ) . Twenty treatment naïve previously treat PCV eye enrol ( one study eye per patient enrol ) . A maximum 10 previously treat eye enrol . Consented , enrol patient follow monthly . All patient receive monthly IAI 2.0 mg intravitreally 3 month ( Baseline , Months 1 2 ) , follow mandatory IAI 2.0 mg every 2 month ( Months 4 , 6 , 8 10 ) 12 month . Patients receive additional IAI treatment ( Months 3 , 5 , 7 , 9 , 11 ) re-treatment criterion meet . Starting Month 3 , patient receive non-anti vascular endothelial growth factor ( VEGF ) rescue therapy ( ie : Photodynamic Therapy ( PDT ) , laser , intravitreal steroid ) pre-defined criterion meet .</detailed_description>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>Males female ≥ 18 year age . Females child bear potential undergo urine pregnancy test require use appropriate method birth control ICG fluorescein angiographic characteristic consistent active , leak PCV subfoveal lesion and/or subfoveal hemorrhage , lipid exudate , PED fluid Best correct early treatment diabetic retinopathy study ( ETDRS ) visual acuity 4 meter 20/20 20/400 ( BCVA ETDRS letter score 85 20 letter study eye ) Lesion Characteristics leak lesion consistent PCV . ( No limitation hemorrhage , fibrosis atrophy ) Clear ocular medium allow photography/angiography Willing able comply clinic visit studyrelated procedure Patients bilateral disease able enroll one eye Provide sign informed consent Any history systemic AntiVEGF therapy Current ocular periocular infection Active intraocular inflammation Any comorbid condition may decrease visual acuity Any patient intraocular surgery within past 30 day condition For treatment naïve patient : No prior antiVEGF , PDT , intravitreal steroid laser ( subfoveal non foveal ) For previouslytreated patient : Prior antiVEGF ( ranibizumab , bevacizumab , pegaptanib ) within 30 day Prior IAI Prior PDT , transpupillary thermal therapy ( TTT ) radiation within 90 day ( maximum 3 PDTs allow ) Prior intravitreal steroid within 90 day Prior nonfoveal laser within 90 day Prior subfoveal laser Patients feature dry agerelated macular degeneration abundant drusen symptoms/demographic feature inconsistent diagnosis PCV Allergy fluorescein , ICG , iodine , shellfish Any condition investigator believe would pose significant hazard patient investigational therapy initiate Participation another simultaneous medical investigation trial History previous subfoveal laser Advanced glaucoma ( IOP &gt; 25 cup/disc ratio &gt; 0.8 ) Pregnant breastfeed woman Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device ( IUD ) ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) *Contraception require men document vasectomy . **Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>